November 26 | 2020

2cureX launches new website

Read more
November 11 | 2020

2cureX presents commercial roadmap 2021 – 2023

Read more
November 11 | 2020

2cureX presents commercial roadmap 2021 – 2023

Read more
November 5 | 2020

Kommuniké från extra bolagsstämma i 2cureX

Read more
November 5 | 2020

Announcement from 2cureX extra general meeting

Read more
October 14 | 2020

Kallelse till extra bolagsstämma i 2cureX AB

Read more
October 14 | 2020

Notice of extraordinary general meeting in 2ureX AB

Read more
October 1 | 2020

Last patient successfully enrolled in the world’s first interventional trial with 3D microtumors as guide for choice of cancer treatment.

Read more
October 1 | 2020

Den sista patienten är registrerad med framgång i världens första interventionsstudie med 3D-mikrotumörer som vägledning för val av cancerbehandling.

Read more
September 14 | 2020

2cureX launches world’s first CE-marked microtumor test service

Read more
September 14 | 2020

2cureX launches world’s first CE-marked microtumor test service

Read more
August 27 | 2020

2cureX AB (“2cureX”) hereby publishes the interim report for the first half of 2020.

Read more
August 27 | 2020

2cureX AB (”2cureX”) offentliggör härmed halvårsrapport för det första halvåret 2020

Read more
August 4 | 2020

Första dag för handel med teckningsoptioner av serie TO1

Read more
August 4 | 2020

First day for trading in TO1 series warrants

Read more
July 13 | 2020

Record date for allotment of warrants of series TO1 is set to July 17, 2020

Read more
July 13 | 2020

Avstämningsdag för tilldelning av teckningsoptioner av serie TO1 bestämd till den 17 juli 2020

Read more